JMP ups revenue estimate for Sangamo

JMP Securities analyst Charles C. Duncan reiterated Sangamo BioSciences, Inc. at market outperform and a $9 price target. The company reported third-quarter financial results that beat JMP's and consensus estimates on both the top and bottom lines. Revenues of $1.8 million came in higher than the analyst's expectations of $1.2 million and above consensus at $1.7 million. Duncan raised his full-year 2006 revenue estimate to $8.7 million from $8.2 million, and lowered his net loss per share expectations to $0.36 from $0.43. Shares of the Richmond, Calif.-based pharmaceutical company were up 34 cents, or 6.45%, at $5.61. (Nasdaq: SGMO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.